More participants = more data = better research = more life!
We invite you to complete a patient survey/registry specific to ALK-positive lung cancer. This is an IRB approved professionally study conducted by researchers at University of Washington and paid for by ALK Positive Inc. All data is de-identified, and will inform oncologists, researchers, patients and advocates. The study launched October 6, 2022. Our target is at least 1000 participants!